Abbott Surges with Strong Q2 Results | Business and Finance News

Abbott just smashed Q2 earnings, posting $1.31 EPS—up from last year—and raised its 2026 profit forecast to $5.45–$5.60 per share. Sales hit $12.59B, driven by strong growth across medical devices, diagnostics, and pharma. Medical devices surged 8.5%, led by electrophysiology (+13%) and diabetes care (+9.5%). Diagnostics exploded 42%, fueled by cancer tests, including Cologuard. Pharma also gained, especially in emerging markets. Nutrition dipped 3% but edged up from Q1. Abbott returned $2.1B to shareholders and shares jumped. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a528642926c7cc5d